Sébastien PELTIER, CEO

Standing among the "100 personalities beyond diabetes".

VALEDIA®

Confirms its potential to reduce the risk of type 2 diabetes.

Inauguration of VALBIOTIS’ R&D Center

The Discovery and Preclinical Research Platform at Riom: a state-of-the-art GLP-standard infrastructure.

S c r o l l

Products

.01

Pipeline

4 products in clinical development

Learn more

.02

VALEDIA® – Prediabetes

Prediabetes
• Reduction of the risk of type 2 diabetes
• Phase IIa clinical study ongoing

Learn more

.03

LpD64

Overweight and /or obesity
• Modulation of intestinal microbiota
• Clinical Phase I/II positive

Learn more

.04

VAL-070

Mild to moderate hypercholesterolemia
• Reduction of blood LDL-cholesterol
• Clinical Phase I/II positive

Learn more

.05

VALEDIA® – Non alcoholic fatty liver

Non-alcoholic fatty liver (NAFL)
• Reduction of NAFL, risk factor for NASH
• Clinical Phase I/II positive

Learn more

Key figures

Patent families filed

4
All exploitation rights obtained

Employees

> 35
75% in R&D

Listed on the Stock Exchange

2017
Euronext Growth

Our last posts

09.11.2018

American Association for the Study of Liver Diseases Congress

En savoir plus
09.10.2018

European Large & Midcap Event 

En savoir plus
03.10.2018

European Association for the Study of Diabetes (EASD) Congress

En savoir plus
27.09.2018

100 portraits beyond diabetes

En savoir plus
Voir tous

VALBIOTIS© listed on the Stock Exchange

Follow us!

See more